Mitomycin Injection Recalled Due to Lack of Sterility Assurance
Vital Care Compounder is recalling 185 syringes of Mitomycin Injection due to lack of sterility assurance discovered during FDA inspection. The product cannot guarantee sterility.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This FDA Class II recall involves a manufacturing defect affecting sterility assurance in an injectable medication. Although no illnesses or injuries have been reported, the product represents a risk-of-harm to patients, meeting the High severity criterion for risk-of-harm products where injury has not yet been reported.
Plain-English summary
Vital Care Compounder is recalling Mitomycin Injection 0.375 mg/mL in 1 mL syringes due to a manufacturing defect. A total of 185 syringes have been recalled.
During an FDA inspection, the agency found that the recalled products were produced in a manner that cannot guarantee their sterility. Sterility is critical for injectable medications, as non-sterile injections could introduce harmful pathogens directly into the patient's bloodstream.
The recalled product was distributed in Alabama, Louisiana, Mississippi, and Tennessee. The affected lot numbers are 60618 (beyond-use date 5/6/2023) and 66536 (beyond-use date 7/8/2023).
Patients who received this medication should contact their healthcare provider immediately. Healthcare providers and pharmacies should remove this product from dispensing and consult with the FDA regarding proper handling and return of recalled units.
The recalled product
- Product
- MITOMYCIN INJECTION 0.375 mg/mL SYR, 0.375 mg/mL solution, 1 mL syringe, Rx only, Vital Care Compounder, 115 S. 40th Ave., Hattiesburg, MS 39402
- Manufacturer
- Pharmacy Plus, Inc. dba Vital Care Compounder
- Category
- Drug — Oncology Injectable
- Hazard
- sterility-defect
- contamination-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lots: 60618
- BUD: 5/6/2023
- 66536
- BUD: 7/8/2023
Distribution
Distributed in 4 states:
- AL
- LA
- MS
- TN
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateSensipar (Cinacalcet Hydrochloride) Tablets Recalled for CGMP Deviations
FDA (Drugs) · 2026-07-01
- ModerateSensipar cinacalcet hydrochloride tablets recalled for CGMP deviations
FDA (Drugs) · 2026-07-01
- ModerateCorlanor ivabradine tablets recalled for presence of foreign substance
FDA (Drugs) · 2026-07-01
- ModerateSensipar Cinacalcet Tablets Recalled Due to CGMP Deviations
FDA (Drugs) · 2026-07-01